Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2019-02-18 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Mayne Pharma announces new indication for Kapanol by TGA 3 pages 423.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Mayne Pharma regarding the approval by the Therapeutic Goods Administration (TGA) of a new indication for their drug KAPANOL for chronic breathlessness. It discusses regulatory approval, clinical study background, and plans for reimbursement application to the Pharmaceutical Benefits Advisory Committee. The content is a corporate announcement about a regulatory milestone and product update rather than a financial report, earnings release, or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is a substantive announcement itself, not just a notice of report availability. The document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about product approval and related corporate information.
2019-02-18 English
Lexette (halobetasol) foam now launched in the US 2 pages 259.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Mayne Pharma about the launch of a pharmaceutical product (LEXETTE foam) in the United States. It contains promotional and product launch information, market context, and company background. There are no financial statements, regulatory filings, voting results, or management changes. The document is relatively short (4180 characters) and serves as a press release or announcement rather than a detailed financial or regulatory report. Therefore, it fits best under the category of a general regulatory announcement or company news rather than a specific financial or governance filing.
2019-02-12 English
Tolsura (SUBA-itraconazole) capsule now launched in the US 3 pages 457.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 January 2019 from Mayne Pharma Group Limited regarding the launch of a pharmaceutical product, TOLSURA (SUBA-itraconazole), in the United States. It includes detailed product information, indications, safety warnings, and contact details. There is no financial data, no mention of earnings, no regulatory filings or certifications, no voting results, no management changes, no merger or acquisition activity, and no reference to any report being attached or published. The content is a corporate announcement about a product launch and related information, which fits the category of a general regulatory announcement or company news. Given the absence of any other specific filing type indicators, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories. The document length (7120 characters) and content confirm it is not a brief report publication announcement or a financial report.
2019-01-29 English
Change of Director's Interest Notice 2 pages 323.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document length is 3260 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the correct classification is Director's Dealing (DIRS).
2018-12-30 English
Employee option exercise 1 page 257.0KB
Transaction in Own Shares Classification · 95% confidence The document is a notification about the exercise of unquoted employee share options by Mayne Pharma Group. It details the number of options exercised, expiry date, exercise price, and the fact that no new shares were issued but forfeited shares were utilized. This is a report of a transaction involving the company's own shares, specifically related to employee options and share scheme activity. It is not a full financial report, earnings release, or regulatory filing about financial performance. It fits the category of Transaction in Own Shares (POS), which covers company buybacks, share issuances, or share scheme transactions.
2018-12-27 English
Change of Director's Interest Notice 2 pages 350.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's acquisition of shares, including dates, number of securities acquired, and value. The content focuses on the personal share transactions of a company director. There is no financial performance data, earnings information, or report publication. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3469 characters, which is consistent with a detailed notice of director's dealings rather than a full report or announcement. Therefore, the correct classification is DIRS.
2018-12-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.